Evidence map›Paper›PMID 32039399›Full record

ReviewJHEP reports : innovation in hepatology2019

Lifestyle modification in NAFLD/NASH: Facts and figures.

Kate Hallsworth, Leon A Adams

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JHEP reports : innovation in hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05474560 (Allopurinol Versus Febuxostat), which is not on this map. Cited by 148 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05474560 phase4completednot on this mapstarted 2022, after this paper: background citation

Allopurinol Versus Febuxostat: A New Approach for Management of Hepatic Steatosis in Metabolic-Associated Fatty Liver Disease

TypeinterventionalSponsorAin Shams UniversityRan2022 to 2023Enrolled90ConditionsNon-Alcoholic Fatty Liver Disease, HyperuricemiaArmsAllopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention
3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Frontiers in nutrition · 2023
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Journal of medicinal food · 2020
    Trial
  20. Article

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kate HallsworthInstitute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Leon A AdamsMedical School, The University of Western Australia, Perth, WA, Australia.

Funding

Department of Health CAT CL-2013-04-010
6 · The paper itself

Abstract

The development of non-alcoholic fatty liver disease is closely linked to lifestyle factors, namely excessive caloric intake coupled with reduced physical activity and exercise. This review aims to examine the evidence behind lifestyle change as a tool to improve hepatic steatosis and liver histology in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Furthermore, potential barriers to adopting lifestyle changes and strategies to overcome these barriers in the clinical setting are discussed.

Indexed as

dietlifestylenon-alcoholic fatty liver diseasenon-alcoholic steatohepatitisphysical activity/exerciseweight loss

Identifiers

PMID32039399
PMCPMC7005657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.